Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,812
  • Shares Outstanding, K 78,583
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,100 K
  • 60-Month Beta 2.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.33
Trade SEEL with:

Options Overview

Details
  • Implied Volatility 112.29%
  • Historical Volatility 69.89%
  • IV Percentile 17%
  • IV Rank 5.08%
  • IV High 352.41% on 03/04/21
  • IV Low 99.46% on 07/22/21
  • Put/Call Vol Ratio 0.21
  • Today's Volume 128
  • Volume Avg (30-Day) 1,015
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 33,395
  • Open Int (30-Day) 33,966

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.25
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -112.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +3.45%
on 07/27/21
3.10 -27.42%
on 07/01/21
-0.39 (-14.77%)
since 06/30/21
3-Month
2.17 +3.45%
on 07/27/21
6.23 -63.88%
on 05/03/21
-3.84 (-63.05%)
since 04/30/21
52-Week
0.56 +301.57%
on 09/24/20
6.60 -65.91%
on 04/27/21
+1.00 (+80.00%)
since 07/30/20

Most Recent Stories

More News
Companies Smashing the Psychedelic Ceiling

/PRNewswire/ -- It's early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
SEEL : 2.25 (-2.60%)
FTRP.TO : 7.74 (+7.50%)
FTRPF : 5.7460 (-2.32%)
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

/PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics...

LKYSF : 0.7778 (+4.08%)
SEEL : 2.25 (-2.60%)
NUMI.VN : 0.970 (+4.30%)
MNMD : 3.06 (+0.99%)
MYCOF : 0.3785 (+8.14%)
TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Seelos Therapeutics to Participate in Two Investor Conferences in August

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today...

SEEL : 2.25 (-2.60%)
Thinking about buying stock in OncoSec Medical, Dare Bioscience, Jaguar Health, Americas Gold and Silver, or Seelos Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS, DARE, JAGX, USAS, and SEEL.

USAS : 1.3600 (-2.16%)
DARE : 1.5400 (+1.32%)
JAGX : 1.4000 (-4.11%)
ONCS : 2.18 (+0.93%)
SEEL : 2.25 (-2.60%)
Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease Pathology

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today...

SEEL : 2.25 (-2.60%)
Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today...

SEEL : 2.25 (-2.60%)
Thinking about buying stock in Bridgeline Digital, Seelos Therapeutics, Vistagen Therapeutics, BioLineRx, or Entera Bio?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLIN, SEEL, VTGN, BLRX, and ENTX.

BLIN : 6.40 (+8.84%)
BLRX : 3.23 (-0.92%)
VTGN : 2.66 (-0.75%)
ENTX : 5.14 (+0.98%)
SEEL : 2.25 (-2.60%)
Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced...

SEEL : 2.25 (-2.60%)
Thinking about buying stock in Stealth BioTherapeutics, BlackBerry, Ideanomics, Seelos Therapeutics, or Altimmune?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, BB, IDEX, SEEL, and ALT.

ALT : 9.07 (+0.11%)
IDEX : 2.37 (-2.07%)
MITO : 1.3800 (unch)
SEEL : 2.25 (-2.60%)
BB : 10.16 (-1.84%)
Thinking about buying stock in Akebia Therapeutics, BlackBerry, Seelos Therapeutics, Canopy Growth Corp, or Aqua Metals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, BB, SEEL, CGC, and AQMS.

AKBA : 2.47 (-1.98%)
CGC : 18.91 (-3.22%)
SEEL : 2.25 (-2.60%)
AQMS : 2.31 (+0.43%)
BB : 10.16 (-1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

3rd Resistance Point 2.48
2nd Resistance Point 2.40
1st Resistance Point 2.33
Last Price 2.25
1st Support Level 2.18
2nd Support Level 2.10
3rd Support Level 2.03

See More

52-Week High 6.60
Fibonacci 61.8% 4.29
Fibonacci 50% 3.58
Fibonacci 38.2% 2.87
Last Price 2.25
52-Week Low 0.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar